Clinical Trial Update: A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating eFT508 alone and with avelumab in microsatellite stable colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avelumab (avelumab)
• eFT508 (eft908? (assumed) placeholder)

Snippet

Sponsor: Effector Therapeutics | Conditions: Microsatellite Stable Relapsed or Refractory Colorectal Cancer | Phase 2 | Status: COMPLETED